Kailera Therapeutics
PublicKailera Therapeutics is now publicly traded
The data on this page reflects Kailera Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Apr 17, 2026
Last Round
Series B
Oct 14, 2025
Total Funding Raised
$1.72B
Company Overview
Kailera Therapeutics is a biopharmaceutical company that develops a diversified pipeline of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions.
Sector
Biotech
Verticals
Life Sciences, LOHAS & Wellness
AI Layer
Non-AI
Keywords
Kailera Therapeutics Comparables
Compare Kailera Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Viking Therapeutics, Inc. | 92% | |
| Structure Therapeutics | 87% | |
| Pfizer | 84% |
For institutional investors. Book with your work email.
Kailera Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Apr 17, 2026 | ||||
| Series B | Oct 14, 2025 | ||||
| Series A | Oct 1, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Kailera Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Sirona Capital | Series B |
| Jefferies | IPO |
| Surveyor Capital | Series B |
| JP Morgan Securities | IPO |
| CPP Investments | Series B |
| Evercore ISI | IPO |
| Bain Capital Life Sciences | Series B, Series A |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 3, 2026
Kailera Therapeutics, Inc. advances development of KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist.
- is_developingNov 3, 2026
Kailera Therapeutics, Inc. is advancing development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, as part of its obesity-focused pipeline in Massachusetts.
- is_developingNov 3, 2026
Kailera Therapeutics, Inc. is advancing four clinical-stage product candidates that use multiple GLP-1-based mechanisms and administration routes to address obesity treatment needs, including ribupatide injection (KAI-9531), KAI-7535, and KAI-4729.
- attends_eventOct 1, 2026
Kailera Therapeutics, Inc. presents new clinical data, including Phase 1 findings for ribupatide injection, at the EASD 2026 Annual Meeting in Italy.
- is_developingSep 16, 2026
Kailera Therapeutics, Inc. is advancing development of KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist.
For institutional investors. Book with your work email.
Kailera Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.